PMID- 21999110
OWN - NLM
STAT- MEDLINE
DCOM- 20120420
LR  - 20161125
IS  - 1744-764X (Electronic)
IS  - 1474-0338 (Linking)
VI  - 11
IP  - 1
DP  - 2012 Jan
TI  - Safety of bivalirudin in patients with coronary artery disease.
PG  - 141-50
LID - 10.1517/14740338.2012.628312 [doi]
AB  - INTRODUCTION: Various limitations of unfractionated heparin (UFH) have triggered 
      a search for new antithrombotic therapies for patients with coronary artery 
      disease (CAD). Bivalirudin is a direct thrombin inhibitor with several 
      pharmacological advantages over UFH and is currently endorsed by practice 
      guidelines, particularly in patients with acute coronary syndromes undergoing 
      percutaneous coronary intervention (PCI). To maximize effectiveness of an 
      antithrombotic regimen and reduce complications, both ischemic and bleeding risks 
      should be known when an antithrombotic strategy is chosen. AREAS COVERED: This 
      review focuses on the safety and tolerability of bivalirudin in patients with CAD 
      in the setting of currently approved indications. Synthesis of evidence has been 
      made from clinical trials, systematic reviews, meta-analyses and registries (1992 
      - 2011). The reader is provided with an overview of pharmacological properties of 
      bivalirudin and its efficacy, with special emphasis on its safety in patients 
      with CAD. EXPERT OPINION: Bivalirudin has an impressive safety profile in CAD 
      patients treated with PCI. Bivalirudin is the antithrombotic of choice in 
      suspected or verified heparin-induced thrombocytopenia. For ST elevation 
      myocardial infarction patients undergoing primary PCI, bivalirudin should become 
      the preferred antithrombotic agent together with early institution of 
      antiplatelet therapy.
FAU - Abdel-Wahab, Mohamed
AU  - Abdel-Wahab M
AD  - Herzzentrum, Segeberger Kliniken GmbH, Am Kurpark 1, 23795 Bad Segeberg, Germany. 
      mohamed.abdel-wahab@segebergerkliniken.de
FAU - Richardt, Gert
AU  - Richardt G
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20111017
PL  - England
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
RN  - 0 (Antithrombins)
RN  - 0 (Hirudins)
RN  - 0 (Peptide Fragments)
RN  - 0 (Recombinant Proteins)
RN  - 9005-49-6 (Heparin)
RN  - TN9BEX005G (bivalirudin)
SB  - IM
MH  - Angioplasty, Balloon, Coronary/methods
MH  - Antithrombins/*adverse effects/pharmacology/therapeutic use
MH  - Coronary Artery Disease/*drug therapy
MH  - Hemorrhage/chemically induced
MH  - Heparin/adverse effects
MH  - Hirudins/*adverse effects/pharmacology
MH  - Humans
MH  - Myocardial Infarction/physiopathology/therapy
MH  - Peptide Fragments/*adverse effects/pharmacology/therapeutic use
MH  - Practice Guidelines as Topic
MH  - Recombinant Proteins/adverse effects/pharmacology/therapeutic use
MH  - Thrombocytopenia/chemically induced
EDAT- 2011/10/18 06:00
MHDA- 2012/04/21 06:00
CRDT- 2011/10/18 06:00
PHST- 2011/10/18 06:00 [entrez]
PHST- 2011/10/18 06:00 [pubmed]
PHST- 2012/04/21 06:00 [medline]
AID - 10.1517/14740338.2012.628312 [doi]
PST - ppublish
SO  - Expert Opin Drug Saf. 2012 Jan;11(1):141-50. doi: 10.1517/14740338.2012.628312. 
      Epub 2011 Oct 17.